Cardiology | |
|---|---|
| Study Name | Principal Investigator |
| Esperion 1002-043– A randomized, double-blind, placebo-controlled study to access the effects
of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in patients
with, or at high risk for, cardiovascular disease who are statin intolerant. Read more. |
Angel Mulkay, MD |
| DAPA ACT HF-TIMI 68 – A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients with Heart Failure with Reduced Ejection Fraction Who Have Been Stabilized During Hospitalization for Acute Heart Failure. Read more. |
Angel Mulkay, MD |
| SAFE-STEMI– Study of access for enhancing percutaneous coronary intervention (PCI) in ST-
elevation myocardial infarction (STEMI) for seniors. Read more. |
Angel Mulkay, MD |
| SELECT-4388– Semaglutide effects on heart disease and stroke in people with overweight or
obesity. Read more. |
Suraj Saggar, DO |
| EMPACT-MI – A streamlined, multicenter, randomized, parallel group, double-blind, placebo-controlled superiority trial to evaluate the effect of EMPAgliflozin on hospitalization for heart failure and mortality in patients with aCuTe Myocardial Infarction. Read more. |
Angel Mulkay, MD |
